-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Fimavacc in Head And Neck Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fimavacc in Head And Neck Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Fimavacc in Head And Neck Cancer Drug Details:Fimavacc is under development for...
-
Product Insights
Bile Duct Cancer (Cholangiocarcinoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Bile Duct Cancer Pipeline Drugs Market Report Overview Bile duct cancer (cholangiocarcinoma) are tumors that occur in the bile duct. Symptoms include discomfort in the tummy area (abdomen), loss of appetite, high temperatures (fevers), and weight loss. Treatment includes chemotherapy and radiation therapy. The Bile Duct Cancer drugs in development market research report provides comprehensive information on the therapeutics under development for Bile Duct Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of...
-
Product Insights
Net Present Value Model: Fostroxacitabine bralpamide
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Fostroxacitabine bralpamide Drug Details fostroxacitabine bralpamide...
-
Track & Monitor
Innovation in Pharmaceuticals: Nucleoside chemical synthesis
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the Pharmaceuticals industry’s Nucleoside chemical synthesis segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered based...
-
Product Insights
Bladder Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Bladder cancer occurs in tissues of the urinary bladder whose symptoms include blood or blood clots in the urine, frequent urination, lower back pain on one side of the body, and burning during urination. Risk factors for bladder cancer include smoking, exposure to substances such as rubber, certain dyes and textiles, paint, and hairdressing supplies, diet rich in fried meats and fat, old age, sex and color, and certain parasitic infections. The Bladder Cancer pipeline market research report provides comprehensive...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – fostroxacitabine bralpamide hydrochloride
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry fostroxacitabine bralpamide hydrochloride Drug Details fostroxacitabine bralpamide (MIV-818) is under development for the treatment...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – MIV-711
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry MIV-711 Drug Details MIV-711 is under development for the treatment of osteoarthritis. The drug...
-
Product Insights
Non-Hodgkin Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Non-Hodgkin lymphoma (also known as non-Hodgkin’s lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in cells called lymphocytes, which are part of the body’s immune system. Symptoms may include night sweats, fever and chills that come and go, itching, putting pressure on the windpipe (trachea) or other airways, abdominal pain or swelling, leading to loss of appetite, constipation, nausea, and vomiting and headache, concentration problems, personality changes, or seizures if cancer affects the brain. Treatment includes surgery,...
-
Product Insights
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression, and developmental events. The Histone Deacetylase 3 pipeline drugs market research report outlays comprehensive information on the Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Histone Deacetylase 3 (SMAP45...
-
Sector Analysis
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
The Histone Deacetylase 2 pipeline drugs market research report outlays comprehensive information on the Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Central Nervous System, Genetic Disorders, Hematological Disorders, Gastrointestinal, Immunology, Infectious Disease, and Musculoskeletal Disorders, which include indications.